So far, this trans-differentiation strategy has been promoted in stroke, AD, Parkinson’s disease (PD), Huntington’s disease, and other neurological diseases to increase neuronal regeneration and improve disease symptoms (Puls et al., 2020; Wu et al., 2020; Zhang et al., 2020), suggesting that NeuroD1 is a potential therapeutic target for future clinical treatment of massive neuronal loss. Here, NEUROD1 is linked to stroke disorder.